Cost analysis of intra-arterial versus intra-venous delivery of bevacizumab for the treatment of recurrent glioblastoma multiforme

Jan Karl Burkhardt, Benjamin J. Shin, Cody D. Schlaff, Howard Riina, John A. Boockvar

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Intra-arterial bevacizumab (IA BV) has been recently identified to be safe in the treatment of recurrent GBM. In this study, we sought to perform a cost analysis of IA BV versus IV BV especially also taking account of patient progression free survival (PFS) and overall survival (OS). We show that IA BV is significantly more cost effective than conventional IV therapy.

Original languageEnglish (US)
Pages (from-to)183-186
Number of pages4
JournalJournal of Experimental Therapeutics and Oncology
Volume9
Issue number3
StatePublished - Dec 29 2011

Fingerprint

Glioblastoma
Costs and Cost Analysis
Disease-Free Survival
Therapeutics
Survival
Bevacizumab

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery
  • Cancer Research

Cite this

@article{cb4ec2ea44bf4abe8f27bfcdd02ca451,
title = "Cost analysis of intra-arterial versus intra-venous delivery of bevacizumab for the treatment of recurrent glioblastoma multiforme",
abstract = "Intra-arterial bevacizumab (IA BV) has been recently identified to be safe in the treatment of recurrent GBM. In this study, we sought to perform a cost analysis of IA BV versus IV BV especially also taking account of patient progression free survival (PFS) and overall survival (OS). We show that IA BV is significantly more cost effective than conventional IV therapy.",
author = "Burkhardt, {Jan Karl} and Shin, {Benjamin J.} and Schlaff, {Cody D.} and Howard Riina and Boockvar, {John A.}",
year = "2011",
month = "12",
day = "29",
language = "English (US)",
volume = "9",
pages = "183--186",
journal = "Journal of Experimental Therapeutics and Oncology",
issn = "1359-4117",
publisher = "Old City Publishing",
number = "3",

}

Cost analysis of intra-arterial versus intra-venous delivery of bevacizumab for the treatment of recurrent glioblastoma multiforme. / Burkhardt, Jan Karl; Shin, Benjamin J.; Schlaff, Cody D.; Riina, Howard; Boockvar, John A.

In: Journal of Experimental Therapeutics and Oncology, Vol. 9, No. 3, 29.12.2011, p. 183-186.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cost analysis of intra-arterial versus intra-venous delivery of bevacizumab for the treatment of recurrent glioblastoma multiforme

AU - Burkhardt, Jan Karl

AU - Shin, Benjamin J.

AU - Schlaff, Cody D.

AU - Riina, Howard

AU - Boockvar, John A.

PY - 2011/12/29

Y1 - 2011/12/29

N2 - Intra-arterial bevacizumab (IA BV) has been recently identified to be safe in the treatment of recurrent GBM. In this study, we sought to perform a cost analysis of IA BV versus IV BV especially also taking account of patient progression free survival (PFS) and overall survival (OS). We show that IA BV is significantly more cost effective than conventional IV therapy.

AB - Intra-arterial bevacizumab (IA BV) has been recently identified to be safe in the treatment of recurrent GBM. In this study, we sought to perform a cost analysis of IA BV versus IV BV especially also taking account of patient progression free survival (PFS) and overall survival (OS). We show that IA BV is significantly more cost effective than conventional IV therapy.

UR - http://www.scopus.com/inward/record.url?scp=84455163173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84455163173&partnerID=8YFLogxK

M3 - Article

C2 - 22070049

AN - SCOPUS:84455163173

VL - 9

SP - 183

EP - 186

JO - Journal of Experimental Therapeutics and Oncology

JF - Journal of Experimental Therapeutics and Oncology

SN - 1359-4117

IS - 3

ER -